Last Updated: 10 Nov 2024
Executive Summary
ADC Therapeutics SA (ADCT) is a clinical-stage oncology company focused on developing Antibody Drug Conjugates (ADCs) for treating hematologic malignancies and solid tumors. The company's lead product candidate, Loncastuximab tesirine, is currently in Phase III clinical trials for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Company Overview
ADC Therapeutics was incorporated in 2014 and is headquartered in Epalinges, Switzerland. The company has a pipeline of ADC candidates targeting various cancer types, including DLBCL, Hodgkin lymphoma, and multiple myeloma. ADC Therapeutics has a collaboration agreement with Johnson & Johnson to develop and commercialize Loncastuximab tesirine.
Fundamental Analysis
Revenue: ADCT reported revenue of $70.7 million in the past twelve months, representing a 27.4% year-over-year growth.
EBITDA: The company's EBITDA loss was $135.6 million in the past twelve months.
EPS: ADCT reported a diluted EPS of -$2.54 in the past twelve months.
Market Cap: ADCT's market capitalization is approximately $2.83 billion.
P/S Ratio: The company's Price-to-Sales ratio is 4.006.
Technical Analysis
52-Week High: $6.04
52-Week Low: $0.36
50-Day Moving Average: $3.02
200-Day Moving Average: $3.657
Beta: 1.602
Short Term Outlook
The stock price of ADCT has been volatile in recent months, trading between $2.50 and $3.50. The company's upcoming Phase III clinical trial results for Loncastuximab tesirine will be a key catalyst for the stock. If positive, the results could drive the stock price higher. However, if the results are negative, the stock price could decline significantly.
Long Term Outlook
ADC Therapeutics has the potential to be a major player in the ADC market. The company's pipeline of ADC candidates targets a wide range of cancer types, and its collaboration with Johnson & Johnson provides access to a global commercial infrastructure. If ADCT can successfully develop and commercialize its ADC candidates, the company could generate significant revenue and profits in the long term.
Analyst Recommendations
According to analysts, ADCT is currently rated as a "Buy." Two analysts have a "Strong Buy" rating, four have a "Buy" rating, and one has a "Hold" rating. The average analyst target price for ADCT is $9.00.
